MX2023009223A - Terapia combinada para el tratamiento del crecimiento celular anormal. - Google Patents
Terapia combinada para el tratamiento del crecimiento celular anormal.Info
- Publication number
- MX2023009223A MX2023009223A MX2023009223A MX2023009223A MX2023009223A MX 2023009223 A MX2023009223 A MX 2023009223A MX 2023009223 A MX2023009223 A MX 2023009223A MX 2023009223 A MX2023009223 A MX 2023009223A MX 2023009223 A MX2023009223 A MX 2023009223A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- cell growth
- abnormal cell
- treating abnormal
- combination therapy
- Prior art date
Links
- 230000002159 abnormal effect Effects 0.000 title abstract 2
- 230000010261 cell growth Effects 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 3
- 229940124647 MEK inhibitor Drugs 0.000 abstract 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 abstract 2
- 229940126638 Akt inhibitor Drugs 0.000 abstract 1
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 abstract 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 abstract 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940126271 SOS1 inhibitor Drugs 0.000 abstract 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 abstract 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 229940121647 egfr inhibitor Drugs 0.000 abstract 1
- 229940124302 mTOR inhibitor Drugs 0.000 abstract 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 239000003197 protein kinase B inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163146369P | 2021-02-05 | 2021-02-05 | |
| US202163146352P | 2021-02-05 | 2021-02-05 | |
| US202163146357P | 2021-02-05 | 2021-02-05 | |
| US202163146395P | 2021-02-05 | 2021-02-05 | |
| US202163146376P | 2021-02-05 | 2021-02-05 | |
| US202163146349P | 2021-02-05 | 2021-02-05 | |
| US202163185695P | 2021-05-07 | 2021-05-07 | |
| US202163185704P | 2021-05-07 | 2021-05-07 | |
| US202163185672P | 2021-05-07 | 2021-05-07 | |
| US202163185651P | 2021-05-07 | 2021-05-07 | |
| PCT/US2022/015262 WO2022170060A1 (en) | 2021-02-05 | 2022-02-04 | Combination therapy for treating abnormal cell growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009223A true MX2023009223A (es) | 2023-08-15 |
Family
ID=82741881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009223A MX2023009223A (es) | 2021-02-05 | 2022-02-04 | Terapia combinada para el tratamiento del crecimiento celular anormal. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240115571A1 (https=) |
| EP (1) | EP4288057A4 (https=) |
| JP (1) | JP2024505680A (https=) |
| KR (1) | KR20230142757A (https=) |
| AU (1) | AU2022216284A1 (https=) |
| BR (1) | BR112023015616A2 (https=) |
| CA (1) | CA3210506A1 (https=) |
| IL (1) | IL304908A (https=) |
| MX (1) | MX2023009223A (https=) |
| WO (1) | WO2022170060A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021206684B2 (en) | 2020-01-10 | 2024-01-18 | Immuneering Corporation | MEK inhibitors and therapeutic uses thereof |
| MX2023012929A (es) * | 2021-05-05 | 2023-11-13 | Huyabio Int Llc | Terapias de combinacion que comprenden inhibidores de shp2 e inhibidores de tirosina cinasa egfr. |
| US20250041298A1 (en) * | 2021-12-02 | 2025-02-06 | Pfizer Inc. | Cdk4 inhibitor for the treatment of cancer |
| IL313653A (en) * | 2022-01-06 | 2024-08-01 | Immuneering Corp | Immuno-oncology inhibitors of MEK and their therapeutic uses |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| CA3262155A1 (en) | 2022-08-11 | 2024-02-15 | Evexta Bio | COMPOUNDS FOR CANCER TREATMENT |
| WO2024148307A1 (en) * | 2023-01-06 | 2024-07-11 | Erasca, Inc. | Raf inhibitor and erk1/2 and/or shp2 inhibitor combination therapy |
| WO2025010287A2 (en) * | 2023-07-03 | 2025-01-09 | Immuneering Corporation | Mek immune oncology inhibitors and therapeutic uses thereof |
| CN116509868B (zh) * | 2023-07-04 | 2023-10-20 | 四川大学华西医院 | Vs6766联合bay293的应用及药物组合物 |
| WO2025168601A1 (en) | 2024-02-05 | 2025-08-14 | Evexta Bio | Quinazoline carboxamide azetidine compounds for use in treating hormone dependent diseases |
| WO2025202854A1 (en) * | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015120289A1 (en) * | 2014-02-07 | 2015-08-13 | Verastem, Inc. | Methods and compositions for treating abnormal cell growth |
| KR20170060042A (ko) * | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| US20190367964A1 (en) * | 2016-02-02 | 2019-12-05 | Dana-Farber Cancer Institute, Inc. | Dissociation of human tumor to single cell suspension followed by biological analysis |
| WO2019195959A1 (en) * | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
| US11633401B2 (en) * | 2018-07-06 | 2023-04-25 | Memorial Sloan Kettering Cancer Center | Combination therapy with MEK inhibitor and CDK4/6 inhibitor to treat pancreatic cancer |
| CN112137994B (zh) * | 2020-09-15 | 2022-10-14 | 中山大学 | 小分子化合物在制备抗丝状病毒药物中的应用 |
-
2022
- 2022-02-04 JP JP2023547408A patent/JP2024505680A/ja active Pending
- 2022-02-04 KR KR1020237029729A patent/KR20230142757A/ko active Pending
- 2022-02-04 WO PCT/US2022/015262 patent/WO2022170060A1/en not_active Ceased
- 2022-02-04 AU AU2022216284A patent/AU2022216284A1/en not_active Abandoned
- 2022-02-04 EP EP22750444.6A patent/EP4288057A4/en active Pending
- 2022-02-04 BR BR112023015616A patent/BR112023015616A2/pt unknown
- 2022-02-04 CA CA3210506A patent/CA3210506A1/en active Pending
- 2022-02-04 MX MX2023009223A patent/MX2023009223A/es unknown
- 2022-02-04 IL IL304908A patent/IL304908A/en unknown
- 2022-02-04 US US18/263,820 patent/US20240115571A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022216284A9 (en) | 2024-09-19 |
| IL304908A (en) | 2023-10-01 |
| KR20230142757A (ko) | 2023-10-11 |
| CA3210506A1 (en) | 2022-08-11 |
| BR112023015616A2 (pt) | 2023-10-31 |
| AU2022216284A1 (en) | 2023-08-17 |
| JP2024505680A (ja) | 2024-02-07 |
| WO2022170060A1 (en) | 2022-08-11 |
| EP4288057A4 (en) | 2025-03-12 |
| US20240115571A1 (en) | 2024-04-11 |
| EP4288057A1 (en) | 2023-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023009223A (es) | Terapia combinada para el tratamiento del crecimiento celular anormal. | |
| MX2023000589A (es) | Terapia de combinacion para tratar el crecimiento celular anormal. | |
| MX2022009347A (es) | Terapia de combinacion para el tratamiento del crecimiento celular anormal. | |
| MX2023015298A (es) | Terapia de combinación de inhibidores de erk1/2 y shp2. | |
| WO2023108110A3 (en) | Combination therapy for treating abnormal cell growth | |
| MX2025003821A (es) | Compuestos con actividad contra tumores mutantes de kras | |
| WO2021243280A3 (en) | Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9 | |
| PH12021552395A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions | |
| CA3183032A1 (en) | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors | |
| Jepsen et al. | Voice, speech, and swallowing outcomes in laser‐treated laryngeal cancer | |
| WO2021162981A3 (en) | Methods and compositions for identifying castration resistant neuroendocrine prostate cancer | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| MX2023012095A (es) | Inhibidores de hdac6 para el uso en el tratamiento de la miocardiopatía dilatada. | |
| WO2022125967A3 (en) | Combination therapies for the treatment of cancer | |
| NO20066054L (no) | behandling med cisplatin og en EGFR-inhibitor | |
| WO2023196978A3 (en) | Myc program as a marker of response to enzalutamide in prostate | |
| WO2024249769A8 (en) | Combination therapy for treating hematological cancers | |
| WO2024026479A3 (en) | Cdk2 inhibitors and methods of using the same | |
| WO2024026483A3 (en) | Cdk2 inhibitors and methods of using the same | |
| WO2024026486A3 (en) | Cdk2 inhibitors and methods of using the same | |
| WO2023055885A3 (en) | Ezh2 inhibition in pancreatic cancer | |
| Berger et al. | Impact of radiotherapy, chemotherapy and surgery in multimodal treatment of locally advanced esophageal cancer | |
| MX2023011956A (es) | Metodo para tratar el cancer de pulmon y el cancer de pulmon de celulas no peque?as. | |
| ZA202307921B (en) | Combination of raf inhibitor and mek inhibitor | |
| MX2022008532A (es) | Inhibidores de hidrocarburo de arilo (ahr) y usos de estos. |